Key result
Doubling of Lp(a) linked to ~8% higher major cardiovascular events risk in angiography patients.
Why the study?
Are Lp(a) and oxidized phospholipids associated with coronary artery disease severity and cardiovascular outcomes in patients undergoing coronary angiography?
Cohort (n=1,098)
Are Lp(a) and oxidized phospholipids associated with coronary artery disease severity and cardiovascular outcomes in patients undergoing coronary angiography?
Answers are grounded in this paper and cite their sources.
In patients undergoing coronary angiography, higher levels of Lp(a) and oxidized phospholipids are significantly associated with multi-vessel CAD and increased risk of incident cardiovascular events.
Background: Lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs) are each independent risk factors for atherosclerotic cardiovascular disease (ASCVD). The extent to which Lp(a) and OxPLs predict coronary artery disease (CAD) severity and outcomes in a contemporary, statin-treated cohort is not well established. Objectives: To evaluate the relationships between Lp(a) particle concentration and OxPLs associated with apolipoprotein B (OxPL-apoB) or apolipoprotein(a) [OxPL-apo(a)] with angiographic CAD and cardiovascular outcomes. Methods: Among 1098 participants referred for coronary angiography in the CASABLANCA study (Catheter Sampled Blood Archive in Cardiovascular Diseases, ClinicalTrials.gov NCT00842868), Lp(a), OxPL-apoB and OxPL-apo(a) were measured. Logistic regression estimated risk of multi-vessel coronary stenoses by Lp(a)-related biomarker level. Cox proportional hazards regression estimated risk of major adverse cardiovascular events (MACE; coronary revascularization, non-fatal MI, non-fatal stroke, and cardiovascular death) in follow-up. Results: Median [IQR] Lp(a) was 26.45 nmol/L [11.39-89.49]. Lp(a), OxPL-apoB, and OxPL-apo(a) were highly correlated (Spearman R≥0.91 for all pairwise combinations). Lp(a) and OxPL-apoB were associated with multi-vessel CAD. Odds of multi-vessel CAD per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.10 (95% CI 1.03-1.18, P=0.006), 1.18 (95% CI 1.03-1.34, P=0.01), and 1.07 (95% CI 0.99-1.16, P=0.07), respectively. All biomarkers were associated with cardiovascular (CV) events. Hazard ratios for MACE per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.08 (95% CI 1.03-1.14, P=0.001), 1.15 (95% CI 1.05-1.26, P=0.004), and 1.07 (95% CI 1.01-1.14, P=0.02), respectively. Conclusions: In patients undergoing coronary angiography, Lp(a) and OxPL-apoB are associated with multi-vessel CAD. Lp(a), OxPL-apoB, and OxPL-apo(a) are associated with incident CV events.
No takes yet. Share an insight, caveat, or question.
Gilliland et al. (2023) conducted a cohort in Coronary artery disease (n=1,098). Lipoprotein(a) and oxidized phospholipids vs. Lower levels (evaluated per doubling) was evaluated on Major adverse cardiovascular events (MACE; coronary revascularization, non-fatal MI, non-fatal stroke, and cardiovascular death) (HR 1.08, 95% CI 1.03-1.14, p=0.001). In patients undergoing coronary angiography, a doubling of Lp(a) was associated with an increased risk of major adverse cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: